Division of Merck & Co. Inc.
Latest From MSD KK
A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.
Keytruda has been approved in Japan for lung cancer, including first-line use, in a batch of new regulatory clearances that also include the country's first prescription drug for irritable bowel syndrome with constipation.
Hot on the heels of Keytruda's US approval for first-line use in lung cancer, and just ahead of the drug’s first local launch, rival PD-1 player Ono has launched a patent infringement suit in Japan against Merck, adding to similar actions brought elsewhere by its global Opdivo partner BMS.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Tony Alvarez, Pres.
- Contact Info
Phone: 03 6272 0088
13th No. 12 Kitanomaru Sq.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.